Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
暂无分享,去创建一个
Yong Chen | Xiaolin Wang | Min Liu | Johannes A Gubat | Ying Li | Lingfeng Min | Caiyun Zhu | Yanliang Chen | Jianqi Yang | Xizhi Zhang | Changjiang Sun | Qingqing Jia
[1] Ftlo Bonin-Cecelia,et al. Phase II: , 2020, The Power of Accountability.
[2] Ying Cheng,et al. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial , 2019, Cancer communications.
[3] Xinchen Sun,et al. Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells , 2019, Cancer Cell International.
[4] T. Okuno,et al. Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer , 2018, The oncologist.
[5] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[6] J. Lagergren,et al. Smoking Cessation and Risk of Esophageal Cancer by Histological Type: Systematic Review and Meta-analysis , 2017, Journal of the National Cancer Institute.
[7] Dong-Wan Kim,et al. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer , 2016, Cancer research and treatment : official journal of Korean Cancer Association.
[8] H. Nagano,et al. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer. , 2016, Anticancer research.
[9] Jing Huang,et al. Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma , 2015, Thoracic cancer.
[10] W. Hong,et al. Raltitrexed-based chemotherapy for advanced colorectal cancer. , 2014, Clinics and research in hepatology and gastroenterology.
[11] N. Sugimoto,et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Harrison,et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. , 2013, European journal of cancer.
[13] M. Cool,et al. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. , 2013, Clinical colorectal cancer.
[14] J. Ajani,et al. Weekly docetaxel, cisplatin, and 5‐fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer , 2010, Cancer.
[15] Y. Shinomura,et al. Phase I/II Study of Docetaxel/Cisplatin/Fluorouracil Combination Chemotherapy Against Metastatic Esophageal Squamous Cell Carcinoma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] K. Wilson,et al. Raltitrexed: optimism and reality , 2009, Expert opinion on drug metabolism & toxicology.
[17] C. Bokemeyer,et al. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. , 2007, Anticancer research.
[18] H. McLeod,et al. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks , 2007, Cancer Chemotherapy and Pharmacology.
[19] J. Feliu,et al. Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer , 2005, British Journal of Cancer.
[20] J. Aparicio,et al. First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer , 2005, Oncology.
[21] R. Rosso,et al. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer. , 2005, Anticancer research.
[22] V. Gebbia,et al. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. , 2004, Anticancer research.
[23] L. Assersohn,et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] J. Aparicio,et al. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] W. Scheithauer,et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma , 2003, British Journal of Cancer.
[26] A. Santoro,et al. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] A. Harris,et al. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] W. Scheithauer,et al. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] S. Sirilerttrakul,et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy. , 2000, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[30] J. Paul,et al. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma , 2000, British Journal of Cancer.
[31] J. Bertino,et al. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.